Affinity between T cell receptors (TCRs) and peptide-MHC complexes has shown to be a poor predictor of functional capacity of T cells. The same holds true for the affinity of chimeric antigen receptors (CARs) or cell engagers (e.g., bispecific antibodies) to their targets. In contrast, cell avidity (or overall cellular binding strength) provides a more complete and physiologically relevant parameter that reflects the bona fide interaction between T cells and tumor cells. Therefore, this interaction can better predict cellular responses in vitro, and drive better, more informed decisions at earlier stages for drug selection and potentially improve clinical outcome.
With the increasing complexity of constructing novel methodologies to further improve clinical outcome, screening methods to quickly identify the best lead candidates is becoming even more essential. One of the main obstacles in the process of measuring avidity as being a critical parameter is the lack of fast, specific, and accurate tool to assess cellular avidity. The z-Movi® Cell Avidity Analyzer is a novel and unique instrument for direct measurement of cell–cell interaction strength using acoustic forces. This new technology provides predictive, reproducible, and fast results at a single-cell level. In this webinar we will demonstrate, using transgenic TCRs, clinically used CARs, and T cell engagers, that data obtained with the z-Movi Cell Avidity Analyzer correlates strongly with standard in vitro assays and pre-clinical mouse experiments. We will review the simple principles behind the z-Movi and demonstrate the great potential for accelerating the development of cellular immunotherapy against cancer.
Instructor and position: Dr. Rogier Reijmers, Principal Scientist and Head of Validation Research at LUMICKS
Costs: Free of charge
Estimated Webinar duration: 1 hour
Join us on Tuesday 23 November at:
10:00 AM CET/5:00 PM CST or
12:00 PM EST/9:00 AM PDT